JP7297738B2 - 疾患の治療のための化合物、その塩、及び方法 - Google Patents
疾患の治療のための化合物、その塩、及び方法 Download PDFInfo
- Publication number
- JP7297738B2 JP7297738B2 JP2020510595A JP2020510595A JP7297738B2 JP 7297738 B2 JP7297738 B2 JP 7297738B2 JP 2020510595 A JP2020510595 A JP 2020510595A JP 2020510595 A JP2020510595 A JP 2020510595A JP 7297738 B2 JP7297738 B2 JP 7297738B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- difluorophenyl
- urea
- methylpiperidin
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023097704A JP7628578B2 (ja) | 2017-08-21 | 2023-06-14 | 疾患の治療のための化合物、その塩、及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548301P | 2017-08-21 | 2017-08-21 | |
| US62/548,301 | 2017-08-21 | ||
| SE1730225 | 2017-08-24 | ||
| SE1730225-8 | 2017-08-24 | ||
| PCT/US2018/000354 WO2019040107A1 (en) | 2017-08-21 | 2018-08-20 | COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097704A Division JP7628578B2 (ja) | 2017-08-21 | 2023-06-14 | 疾患の治療のための化合物、その塩、及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531505A JP2020531505A (ja) | 2020-11-05 |
| JP2020531505A5 JP2020531505A5 (https=) | 2021-09-24 |
| JP7297738B2 true JP7297738B2 (ja) | 2023-06-26 |
Family
ID=63840976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020510595A Active JP7297738B2 (ja) | 2017-08-21 | 2018-08-20 | 疾患の治療のための化合物、その塩、及び方法 |
| JP2023097704A Active JP7628578B2 (ja) | 2017-08-21 | 2023-06-14 | 疾患の治療のための化合物、その塩、及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097704A Active JP7628578B2 (ja) | 2017-08-21 | 2023-06-14 | 疾患の治療のための化合物、その塩、及び方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11345693B2 (https=) |
| EP (2) | EP3672954B1 (https=) |
| JP (2) | JP7297738B2 (https=) |
| KR (1) | KR102692233B1 (https=) |
| CN (2) | CN117466803A (https=) |
| AU (1) | AU2018321546B2 (https=) |
| BR (1) | BR112020003477A2 (https=) |
| CA (1) | CA3071644A1 (https=) |
| DK (1) | DK3672954T3 (https=) |
| ES (1) | ES3042110T3 (https=) |
| FI (1) | FI3672954T3 (https=) |
| HU (1) | HUE073569T2 (https=) |
| IL (1) | IL272444B (https=) |
| LT (1) | LT3672954T (https=) |
| MX (1) | MX2020001757A (https=) |
| PL (1) | PL3672954T3 (https=) |
| PT (1) | PT3672954T (https=) |
| RS (1) | RS67273B1 (https=) |
| SG (1) | SG11202001062XA (https=) |
| SI (1) | SI3672954T1 (https=) |
| WO (1) | WO2019040107A1 (https=) |
| ZA (1) | ZA202001717B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023116691A (ja) * | 2017-08-21 | 2023-08-22 | アカディア ファーマシューティカルズ インコーポレーテッド | 疾患の治療のための化合物、その塩、及び方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3672960A2 (en) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and their use for the treatment of diseases |
| ES2906868T3 (es) * | 2019-05-22 | 2022-04-20 | Zakl Farmaceutyczne Polpharma S A | Intermedio farmacéutico para preparar pimavanserina |
| WO2020249117A1 (zh) * | 2019-06-12 | 2020-12-17 | 华东理工大学 | 抗高血压的多元醇化合物及其衍生物 |
| CN113214231B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其医疗应用 |
| CN115677723B (zh) * | 2020-01-21 | 2024-06-04 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用 |
| WO2021147818A1 (zh) * | 2020-01-21 | 2021-07-29 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用 |
| CN113214141B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其制备和应用 |
| US12527775B2 (en) | 2020-03-26 | 2026-01-20 | Shionogi & Co., Ltd. | Heteroaromatic derivatives having serotonin receptor binding activity |
| CN111548257B (zh) * | 2020-05-28 | 2022-11-15 | 安道麦马克西姆有限公司 | 一种（4-异丙氧基-2-甲基）苯基异丙基酮的制备方法 |
| CN114728933B (zh) * | 2020-07-22 | 2023-06-16 | 山东绿叶制药有限公司 | 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用 |
| JP7741820B2 (ja) * | 2020-12-28 | 2025-09-18 | 塩野義製薬株式会社 | セロトニン受容体結合活性を有する環状アミン誘導体 |
| CN113292484B (zh) * | 2021-06-04 | 2022-11-15 | 沈阳药科大学 | 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用 |
| CA3228653A1 (en) * | 2021-08-11 | 2023-02-16 | Monali BANERJEE | Small molecule urea derivatives as sting antagonists |
| EP4570793A1 (en) * | 2022-08-03 | 2025-06-18 | Luye Innomind Pharma Shijiazhuang Co., Ltd. | 5-ht2a receptor inverse agonist, and preparation method therefor and use thereof |
| WO2024067304A1 (zh) * | 2022-09-28 | 2024-04-04 | 瀚远医药有限公司 | 一种具有Sigma2和5HT2A抑制活性的化合物及用途 |
| WO2024105007A1 (en) * | 2022-11-15 | 2024-05-23 | Samsara Therapeutics Inc. | Autophagy inducing compounds and uses thereof |
| WO2025029990A1 (en) | 2023-08-02 | 2025-02-06 | Acadia Pharmaceuticals Inc. | 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht |
| WO2025162237A1 (zh) * | 2024-02-02 | 2025-08-07 | 绿叶嘉奥制药石家庄有限公司 | 一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533813A (ja) | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ，インコーポレーテッド | セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体 |
| JP2008514642A (ja) | 2004-09-27 | 2008-05-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| WO2008141057A1 (en) | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
| WO2009039461A2 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| JP2010527371A (ja) | 2007-05-15 | 2010-08-12 | アカドイア プハルマセウチカルス インコーポレーテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドならびにその酒石酸塩および各種の結晶形の合成 |
| WO2010111353A1 (en) | 2009-03-25 | 2010-09-30 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| JP2010540454A (ja) | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ，インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1998A (en) | 1841-03-12 | Refrigerator | ||
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| ES2278729T3 (es) | 2000-03-06 | 2007-08-16 | Acadia Pharmaceuticals Inc. | Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina. |
| GB0108099D0 (en) * | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| DK2009000T3 (da) | 2003-01-16 | 2011-09-05 | Acadia Pharm Inc | Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme |
| GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| CA2630860A1 (en) * | 2005-11-25 | 2007-05-31 | Galapagos Sas | Urea derivatives useful as calcium receptor modulators |
| TW200831517A (en) | 2006-12-15 | 2008-08-01 | Astrazeneca Ab | Chemical compounds |
| KR100878446B1 (ko) | 2007-06-07 | 2009-01-13 | 일동제약주식회사 | 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법 |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| SG11201605757SA (en) | 2013-12-20 | 2016-08-30 | Inst Drug Discovery | Substituted amino triazoles, and methods using same |
| CN104844502B (zh) | 2015-06-05 | 2018-07-31 | 齐鲁师范学院 | 一种匹莫范色林的制备方法 |
| ES2890492T3 (es) | 2015-07-20 | 2022-01-20 | Acadia Pharm Inc | Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C |
| CN105481757A (zh) | 2015-12-25 | 2016-04-13 | 北京康立生医药技术开发有限公司 | 一种哌马色林的制备方法 |
| MX2020001757A (es) | 2017-08-21 | 2020-09-07 | Acadia Pharm Inc | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. |
| EP3672960A2 (en) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and their use for the treatment of diseases |
-
2018
- 2018-08-20 MX MX2020001757A patent/MX2020001757A/es unknown
- 2018-08-20 JP JP2020510595A patent/JP7297738B2/ja active Active
- 2018-08-20 SG SG11202001062XA patent/SG11202001062XA/en unknown
- 2018-08-20 BR BR112020003477-0A patent/BR112020003477A2/pt unknown
- 2018-08-20 HU HUE18786069A patent/HUE073569T2/hu unknown
- 2018-08-20 DK DK18786069.7T patent/DK3672954T3/da active
- 2018-08-20 CN CN202311171603.3A patent/CN117466803A/zh active Pending
- 2018-08-20 CN CN201880062080.XA patent/CN111132976B/zh active Active
- 2018-08-20 EP EP18786069.7A patent/EP3672954B1/en active Active
- 2018-08-20 PT PT187860697T patent/PT3672954T/pt unknown
- 2018-08-20 AU AU2018321546A patent/AU2018321546B2/en active Active
- 2018-08-20 PL PL18786069.7T patent/PL3672954T3/pl unknown
- 2018-08-20 RS RS20250888A patent/RS67273B1/sr unknown
- 2018-08-20 SI SI201831265T patent/SI3672954T1/sl unknown
- 2018-08-20 CA CA3071644A patent/CA3071644A1/en active Pending
- 2018-08-20 ES ES18786069T patent/ES3042110T3/es active Active
- 2018-08-20 LT LTEPPCT/US2018/000354T patent/LT3672954T/lt unknown
- 2018-08-20 KR KR1020207006599A patent/KR102692233B1/ko active Active
- 2018-08-20 WO PCT/US2018/000354 patent/WO2019040107A1/en not_active Ceased
- 2018-08-20 EP EP25195295.8A patent/EP4635568A3/en active Pending
- 2018-08-20 FI FIEP18786069.7T patent/FI3672954T3/fi active
-
2020
- 2020-02-04 IL IL272444A patent/IL272444B/en unknown
- 2020-02-21 US US16/797,611 patent/US11345693B2/en active Active
- 2020-03-18 ZA ZA2020/01717A patent/ZA202001717B/en unknown
-
2022
- 2022-05-27 US US17/827,092 patent/US12139477B2/en active Active
-
2023
- 2023-06-14 JP JP2023097704A patent/JP7628578B2/ja active Active
-
2024
- 2024-09-27 US US18/900,015 patent/US20250197385A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533813A (ja) | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ，インコーポレーテッド | セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体 |
| JP2008514642A (ja) | 2004-09-27 | 2008-05-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| JP2008514627A (ja) | 2004-09-27 | 2008-05-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドの塩及びその調製 |
| WO2008141057A1 (en) | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
| JP2010527371A (ja) | 2007-05-15 | 2010-08-12 | アカドイア プハルマセウチカルス インコーポレーテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドならびにその酒石酸塩および各種の結晶形の合成 |
| WO2009039461A2 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| JP2010540454A (ja) | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ，インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
| WO2010111353A1 (en) | 2009-03-25 | 2010-09-30 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023116691A (ja) * | 2017-08-21 | 2023-08-22 | アカディア ファーマシューティカルズ インコーポレーテッド | 疾患の治療のための化合物、その塩、及び方法 |
| JP7628578B2 (ja) | 2017-08-21 | 2025-02-10 | アカディア ファーマシューティカルズ インコーポレーテッド | 疾患の治療のための化合物、その塩、及び方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7297738B2 (ja) | 疾患の治療のための化合物、その塩、及び方法 | |
| US7494992B2 (en) | Antiparasitic terpene alkaloids | |
| WO2019040106A2 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
| KR20150060713A (ko) | 이환형 유도체 | |
| CA2841458A1 (en) | Tricyclic heterocyclic compounds and jak inhibitors | |
| KR20150126036A (ko) | 오토탁신 억제제로서의 신규한 옥타하이드로-피롤로[3,4-c]-피롤 유도체 및 이의 유사체 | |
| KR102822532B1 (ko) | 축환 락탐 유도체 | |
| WO2019040105A2 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| EP2632924A1 (en) | Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists | |
| US11440884B2 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| EA042461B1 (ru) | Соединения, их соли и способы лечения заболеваний | |
| JP2021119130A (ja) | 縮環ラクタム誘導体からなる医薬 | |
| WO2016171181A1 (ja) | ２位置換縮合ピラゾール誘導体 | |
| WO2026010789A1 (en) | 2,4-diphenyl-3,4-dihydroquinazoline derivatives and related compounds as d2 dopamine receptor-selective antagonists | |
| EA046816B1 (ru) | Конденсированное производное лактама | |
| HK40046099A (en) | Fused ring lactam derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210811 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210811 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230417 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230516 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230614 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7297738 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |